13 recruiting. 13 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 13 |
| Phase 1 | 5 | Recruiting 5 |
Follow Fibrosarcoma: new trials by email Literature Review of Fibrosarcoma trials Research Report on Fibrosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas Selumetinib + ZEN-3694 ± Durvalumab - MPNST, NF1 | Phase 2 | Recruiting | University of Alabama at Birmingham | 41 | 2026-08-04 | 2026-08-24 |
| Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 1 / Phase 2 | Recruiting | Ankit Mangla, MD | 17 | 2026-08-01 | 2026-08-11 |
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) | Phase 1 / Phase 2 | Recruiting | AeRang Kim | 45 | 2026-06-01 | 2026-07-27 |
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2026-01-26 | 2026-01-28 |
| Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma preoperative, Quality of life, Functional outcome - Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 110 | 2026-01-26 | 2026-01-28 |
| IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) Tislelizumab+liposomal doxorubicin+ifosfamide - Soft Tissue Sarcomas, Angiosarcoma | Phase 2 | Recruiting | Fudan University | 45 | 2025-02-25 | 2026-01-08 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| SPEARHEAD-3 Pediatric Study Afamitresgene autoleucel - Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) | Phase 1 / Phase 2 | Recruiting | USWM CT, LLC | 20 | 2023-09-01 | 2026-08-11 |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors Selinexor - Wilms Tumor, Rhabdoid Tumor | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2023-08-01 | 2026-10-23 |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors TNG462, Pembrolizumab - Locally Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 225 | 2023-05-26 | 2026-09-08 |
| A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) ASTX727 - Malignant Peripheral Nerve Sheath Tumors (MPNST) | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 25 | 2021-04-29 | 2026-02-05 |
| A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin - Sarcoma, Myxofibrosarcoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2020-04-01 | 2026-04-23 |
Neurofibrosarcoma (10) · Sarcoma (8) · Leiomyosarcoma (5) · Liposarcoma (5) · Sarcoma, Synovial (5) · Dermatofibrosarcoma (4) · Histiocytoma, Malignant Fibrous (4) · Hemangiosarcoma (3) · Desmoplastic Small Round Cell Tumor (2) · Neurofibromatosis 1 (2) · Osteosarcoma (2) · Cholangiocarcinoma (1) · Chondrosarcoma, Extraskeletal Myxoid (1) · Disorders of Sex Development (1)
Neoplasms (13) · Neoplasms by Histologic Type (13) · Neoplasms, Connective Tissue (13) · Neoplasms, Connective and Soft Tissue (13) · Neoplasms, Fibrous Tissue (13) · Neoplasms, Nerve Tissue (10) · Nervous System Diseases (10) · Nervous System Neoplasms (10) · Neurofibroma (10) · Neuromuscular Diseases (10) · Peripheral Nervous System Diseases (10) · Peripheral Nervous System Neoplasms (10) · Nerve Sheath Neoplasms (9) · Neoplasms, Muscle Tissue (6)
AZD 6244 (2) · Doxorubicin (2) · Ifosfamide (2) · pembrolizumab (2) · selinexor (2) · Dactinomycin (1) · Injections (1) · Proton Therapy (1) · Quality of Life (1) · decitabine and cedazuridine drug combination (1) · pazopanib (1)
Memorial Sloan Kettering Cancer Center (3) · Oslo University Hospital (2) · AeRang Kim (1) · Ankit Mangla, MD (1) · Fudan University (1) · HRYZ Biotech Co. (1) · St. Jude Children's Research Hospital (1) · Tango Therapeutics, Inc. (1) · USWM CT, LLC (1) · University of Alabama at Birmingham (1)
United States (9) · China (2) · Norway (2) · France (1) · Spain (1)
Ivar Hompland, MD, PhD (2) · Kjetil Boye, MD, PhD (2) · AeRang Kim, MD, PhD (1) · Ankit Mangla, MD (1) · Edmund Bartlett, MD (1) · Fiorella Iglesias Cardenas, MD (1) · Jessica Gartrell, MD (1) · Maxim Pimpkin, MD (1) · Michael Ortiz, MD (1) · Ping Chi, MD, PhD (1) · Xing Zhang (1) · Zhang Xing (1)